Did you know that approximately 38,000 Americans are diagnosed with HIV each year? Without intervention, nearly 400,000 more Americans will be newly diagnosed with HIV over 10 years, despite the availability of tools to prevent transmissions through sex.1 Primary care providers can play a key role in preventing new diagnoses and helping to end the HIV epidemic. PrEP is a medication routinely taken before potential exposure to HIV to reduce someone’s chances of acquiring it through sex.2 Discussions about PrEP are a crucial part of comprehensive sexual health and HIV prevention strategies, alongside other measures like condom use and regular testing.2 About 25 percent of individuals visit a physician less than once a year, rarely, or never.4 As HIV continues to be an important aspect of public health, PrEP can help individuals stay HIV negative.3 Your conversation could be the only time someone is informed about PrEP.
Learn more in this report, The Preventative Power of HIV PrEP, an essential resource providing a comprehensive overview of HIV PrEP and its critical role in helping to prevent HIV transmission through sex. This report educates on the HIV epidemic and highlights stigma and barriers to PrEP uptake, while offering actionable steps for integrating HIV prevention and PrEP education into clinical practice. Continue Reading in English or Spanish.
1. HIV.gov. EHE Overview. Updated March 20, 2025. Accessed July 18, 2025. https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview 2. Centers for Disease Control and Prevention. HIV Nexus: CDC resources for clinicians. Updated February 10, 2025. Accessed July 31, 2025. https://www.cdc.gov/hivnexus/hcp/prep/index.html 3. Bosh KA, Hall HI, Eastham L, Daskalakis DC, Mermin HJ. Morbidity and Mortality Weekly Report (MMWR): Estimated annual number of HIV infections—United States, 1981-2019. Centers for Disease Control and Prevention. Published June 4, 2021. Accessed July 31, 2025. https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7022a1-H.pdf 4. Data on File. Published Oct. 2021 . Accessed Aug. 4, 2025.
From Gilead Sciences, Inc., an ACOFP Corporate Council Roundtable Member
